Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone
Adverse events: most commonly occurring events (occurring in at least 10% of participants) · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted8 studies · 1057 participantsModerate